key: cord-1025507-98ga82h0 authors: Kumar, A.; Prasad, G.; Srivastav, S.; Gautam, V. K.; Sharma, N. title: A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients date: 2020-07-29 journal: nan DOI: 10.1101/2020.07.23.20160424 sha: ebf7c0b3ae6d75c27b8b6bd7ff0ade71d00c38da doc_id: 1025507 cord_uid: 98ga82h0 Background Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. Ayurveda has been recommended by preventative and clinical management guidelines in India and several clinical trials are ongoing. But there is no study to assess impact of Ayurveda on Covid-19. Methods Objective of present study was to evaluate the clinical outcome in Covid-19 confirmed asymptomatic to mild symptomatic patients who had received Ayurveda and compare with control (who has not received Ayurveda or any support therapy). Patients having Ayurveda intervention (Guduchi Ghan Vati-extract of Tinospora cordifolia) were included from Jodhpur Covid Care Centre and non-recipients were taken from Jaipur Covid Care Centre between May 15 to June 15, 2020. Total 91 patients, who were asymptomatic at the time of hospital admission and between 18 -75 years of age, were included in the study to analyse retrospectively. Results In control group, 11.7% developed mild symptoms after average 1.8 days and none in Ayurveda group reported any symptoms. Significant difference was reported between the group of patients taking Guduchi Ghan Vati (n=40) and patients in standard care (n=51) in terms of virologic clearance at day-7 (97.5% vs 15.6% respectively; p=0.000), at day 14 (100% vs 82.3%) days to stay in hospital ( 6.4 vs 12.8 respectively; p< 0.0001) . Conclusion Results of the study suggest that Guduchi Ghan Vati, a common and widely used Ayurveda preparation, could benefit treating asymptomatic Covid-19 patients. Larger, randomised controlled Trials are required to confirm the findings. Keywords: Ayurveda, Guduchi Ghan Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19) 1 , spread to most countries within short span of time and was declared a pandemic on the March 11, 2020 by World Health Organisation 2 . As of the time of this writing, over 4.5 million cases of COVID-19 have been reported spanning 181 countries or regions and contributing to over 294K deaths. 3 Covid-19 outbreak became a global health crisis which is unparalleled in modern history with most locked down most of the world for months. Despite the contact and rigorous efforts from world scientific experts, there are currently no proven prophylaxis for those who have been exposed to Covid-19 nor treatment for those who go on to develop COVID-19. WHO has recommended symptomatic management to help relieve symptoms, for severe cases, treatment should include care to support vital organ functions and no specific anti-viral treatment for COVID. 4, 5 However, there are claims from various quarters, especially from Traditional Chinese Medicine (TCM) 6 , Korean oriental medicine 7 and Indian systems of medicine, collectively known as AYUSH 8 (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy). Ayurveda, a traditional system of medicine, originated in India more than 3000 years ago. The term Ayurveda is derived from the Sanskrit words Ayu (life) and Veda (science or knowledge). The classic Ayurveda text Charaka Samhita, mentioned about epidemic management and defines immunity as the ability to preventing and arresting the progression of disease for maintaining homeostasis. 9 In India, several initiatives have been taken to utilize the vast potential of Ayurveda in this pandemic. In India, an advisory on Coronavirus suggests several preventive management steps as per Ayurvedic practices, and several medicines for symptomatic management of Coronavirus infection. 10 In Ayurvedic Rasayana, many medicinal plants are valued for their therapeutic potential and have been scientifically investigated with promising results 11, 12 . Based on the recommendation by Ministry of AYUSH, Govt of India. Guduchi Ghan Vati, an Ayurvedic preparation, administered in various trials and hospital settings as an adjuvant 13 due to its antimicrobial and immunomodulator properties best described in traditional text 14 and various scientific reviews 15 . To date, there is no research study to mainly focus on the viral shedding duration, clinical course and Ayurveda treatment efficacy of COVID 19 patients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. Patients diagnosed with COVID-19 in the past 48 hours, asymptomatic at the time of hospital admission, between age of 18 years to 75 years were included in the study from both centres. Patients treated with anti-viral or antibiotic for any reasons, clinical condition requiring intensive care, mild to moderate symptoms at the time of hospitalisation were excluded. Patients in both, Ayurveda and standard care were kept in isolation and supervised as per recommended guidelines. Since the early outbreak, many Ayurveda preparations were given in the community as prophylaxis, early management and for preventing clinical complications. Ayurveda given in the study group was part of an ongoing community initiative where Guduchi Ghan Vati was given orally to Covid patients in total dose of 1000mg daily equally divided in two doses for 2-weeks. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint Nasopharyngeal swab specimens were obtained from all suspected patients. Laboratory confirmed COVID 19 cases who had no symptoms at the time of hospital admissions were followed retrospectively in both Ayurveda and Standard care sites. Data were extracted from the medical records and were filed in pre-designed case forms. Data analysing team were blinded to intervention arms. Demographic, clinical, laboratory and outcome data were obtained. All the patients were followed for 14-days period. The primary endpoint was virologic clearance. The secondary endpoints were full recovery (recovery of clinical symptoms and signs, virologic clearance) and stay in hospital, discharge or admission to the intensive care unit (ICU) and death. The time to virologic clearance indicates the duration from the first Covid positive result to the first Covid negative result. The full stay in hospital is the duration from the admission with first confirmed test to the second Covid negative result (two tests with the difference of 4 day) where patients were discharged. Continuous and categorical variables are presented as the mean (SD) and n (%), respectively. The Mann-Whitney U test, chi squared test or Fisher's exact test were used to compare the differences between two subgroups where appropriate. Analyses were carried out using SPSS statistical software, version 16.0 (IBM). A p value of <0.05 was set as the threshold for statistical significance. In total, 91 hospitalized COVID 19 asymptomatic patients (40 patients taking Guduchi Ghan Vati and 51 patients in standard care) were enrolled in this study. Of them, the median age of patients was 46 years (range 19-72). Sample were only taken from Covid care centres where asymptomatic, mild to moderate patients were admitted. Pregnancy, post-natal or lactating mothers are admitted to separate hospital in case of Covid exposure or confirmation. All demographic and clinical characteristics of patients are shown in Table 1 . There weren't significant changes reported between two groups and none had any symptoms at the time of confirmation and hospital admission. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint Moderate or severe anaemia 3 (7.5) 2 (3.9) Thyroid disease 1 (2.5) 0 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint At the time of admission, both group participants were asymptomatic. In standard care, 11 .7% patients developed mild symptoms of Cough (7.8%), Fatigue (7.8%), Nasal congestion (1.9%), Nauseas (1.9%), vomiting (1.9%) in 1-3 days (mean 1.8) after hospital admission. In Patients receiving Ayurveda intervention, none had reported any fever, had any complications needing symptomatic therapies, support therapy or oxygen support. (Table 3 ) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint In addition, statistically significant results were observed between the time to stay in hospital and Ayurveda intervention (Fisher's exact test, p = 0.0002). The median time to virologic clearance via Kaplan-Meier survival analysis was 5 days in those receiving Ayurveda, and 12 days in those not receiving (P = .0.001). There were no side effect or adverse events reported in patients taking Guduchi Ghan Vati. Pregnancy, breastfeeding, scheduled surgery, autoimmune disorders, immunosuppressants may cause concerns with the use of Guduchi Ghan Vati. None of these contraindications were present in the study population. Due to ethical reasons, and first study results of efficacy of Guduchi Ghan Vati was evident in retrospective analysis, we decide to share our findings with the clinical experts and scientific community, given the urgent need for an effective drug against Covid-19. Present study found that Guduchi Ghan Vati (Ayurveda preparation) is effective in clearing viral nasopharyngeal carriage of COVID-19 patients in medical 5 days, in almost all patients. These results are of great importance because a recent study has shown that the mean duration of viral shedding in patients suffering from COVID-19 in asymptomatic to mild symptoms is 14-21 days (even 37 days for the longest duration) 16 . Previous study also confirms that asymptomatic patients have longer treatment cycle (16 days) compared to moderate Covid-19 case (13 days). 17 Present study shorten the treatment period to 6 days in asymptomatic Covid-19 confirmed cases those who used Ayurveda intervention. There is no previous clinical study available on efficacy of Ayurveda treatment for Covid-19, present results are promising and open the possibility of an international strategy to decisionmakers to fight this emerging viral infection in real-time. Ayurveda herb (Tinospora cordifolia) used in the study is widely available worldwide with no side effect reported. We therefore recommend that COVID-19 asymptomatic patients can be treated with to cure their infection and to limit the transmission of the virus to other people in order to curb the spread of COVID-19 in the world. Our study has some limitations including a small sample size, limited long-term outcome follow-up, however in the current context, we believe that our results should be shared with the scientific community. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint The retrospective design of our study was major limitation, including the small sample size in both groups. Potential source of bias may also be a concern, given the retrospective design of the study. In conclusion, to the best of our knowledge, we present the first data on the efficacy and safety of Guduchi Ghant Vati (Ayurveda Preparation) on asymptomatic Covid-19 patients. Furthermore, we can confirm that potential of Guduchi Ghan Vati treatment may reduce the duration of viral shedding and prevent the disease from worsening symptoms or clinical condition. These findings may help further to plan larger randomised controlled trails to confirm finding of present study. For now, this can help in management of the Covid-19 outbreak. Study was approved by Institutional Ethics Committee University College of Ayurveda, Dr. Sarvapalli Radhakrishnan Rajasthan Ayurved University , Jodhpur to access and analyse data records. Requirement of consent was waived due to retrospective design, de-identifying data of patients and urgent need to evaluate outcome. Emerging coronaviruses: genome structure, replication, and pathogenesis Novel Coronavirus (2019-nCoV) situation reports -World Health Organization (WHO) Situation Report -174-World Health Organisation (WHO) Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus emergencycommittee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) Centers for Disease Control and Prevention . 2020. 2019 Novel Coronavirus China is promoting coronavirus treatments based on unproven traditional medicines Announcement of the first version of Oriental Medicice Clinical Practice Guideline by the National University Network of Traditional Medicine Department of Internal Medicine Ayurveda rasayana in prophylaxis of covid-19 Charaka Samhita, Chaukhamba Surbharati Ayurveda's Immunity Boosting Measures for Self-care During COVID 19 Immunomodulators: a review of studies on Indian medicinal plants and synthetic peptides. Part I: medicinal plants Proc Indian Natl Sci Rasayana Concept: Clues from immunomodulatory therapy AYUSH2020 Pdf Available at New Delhi: Department Of AYUSH, Ministry of Health and FW Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects. Recent Pat Endocr Metab Immune Drug Discov Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Asymptomatic Covid-19 have longer treatment cycle than All authors thank Dr. Parashar Sharma, Samta Andolan Prakoshtha (India), and Dr. Jaydeep No conflicts to declare by authors.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint Acad, 65 (1999), pp. 179-204 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.23.20160424 doi: medRxiv preprint